Dacryocystitis Market to Reach $2.13 Billion by 2035

Dacryocystitis market was valued at $1.35 billion in 2025 and is expected to reach $2.13 billion by 2035, registering a CAGR of 4.8% during the forecast period from 2026 to 2035. The market is expanding due to the increasing burden of nasolacrimal duct obstruction and associated ocular infections, which remain the primary underlying cause of the condition. This is directly influencing the demand for both antibiotic therapies and surgical procedures, particularly in chronic and recurrent cases. A large proportion of patients progress from obstruction to infection, creating a continuous treatment cycle across acute and chronic segments. In addition, delayed diagnosis in developing regions is leading to higher surgical intervention rates, further supporting market growth. This clinical progression from obstruction to infection is establishing a steady and recurring demand base across treatment types within the market.

Browse the full report description of “Dacryocystitis Market Size, Share & Trends Analysis Report by Treatment (Topical Antibiotics, Systemic Antibiotics, Surgical Procedures, Conservative Management, and Others), by Application (Acute Dacryocystitis, Chronic Dacryocystitis, Congenital Dacryocystitis, and Others), by End-User (Hospitals, Ambulatory Surgical Centers, Ophthalmology Clinics / Eye Care Centers, Pharmacies, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/dacryocystitis-market

In terms of statistical support, clinical evidence indicates that approximately 96.23% of dacryocystitis cases are linked to primary acquired nasolacrimal duct obstruction, highlighting its central role in disease development. Furthermore, hospital-based data shows a prevalence rate of 19.5 cases per 10,000 patients, confirming a consistent patient pool requiring treatment. Chronic dacryocystitis accounts for over 86% of cases, indicating prolonged disease duration and repeated treatment needs. In pediatric populations, the incidence of dacryocystitis reaches 243 per 100,000 children with congenital nasolacrimal duct obstruction, reinforcing demand across age groups. Additionally, regional data suggests that 3–9% of populations may present lacrimal sac abnormalities, further expanding the addressable patient base.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Treatment
  • Application
  • End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc., Alcon Inc., Bausch Health Companies Inc., Johnson & Johnson Services, Inc., Novartis AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dacryocystitis Market Report Segment

By Treatment

• Topical Antibiotics
• Systemic Antibiotics (Oral and Intravenous)
• Surgical Procedures
• Conservative Management (Warm Compress, Lacrimal Sac Massage)
• Others

By Application

• Acute Dacryocystitis
• Chronic Dacryocystitis
• Congenital Dacryocystitis
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Ophthalmology Clinics / Eye Care Centers
• Pharmacies
• Others

Global Dacryocystitis Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dacryocystitis-market